-
2023-503692-24-00
5
2024-09-25
Cutaneous Lupus Erythematosus
-
2022-500571-32-00
4
2024-05-15
Early-Stage Unfavorable Classical Hodgkin Lymphoma
-
2023-505446-25-00
9
2024-03-20
Chronic Spontaneous Urticaria
-
2023-503288-40-00
5
2024-01-26
Unresectable or Metastatic Melanoma
-
2023-503309-13-00
5
2023-11-29
Moderate-to-Severe Thyroid Eye Disease
-
2022-502634-52-00
5
2023-05-16
prostate cancer
-
2024-513462-19-00
5
2023-03-30
Refractory Chronic Cough, Including Unexplained Chronic Cough
-
2024-510818-33-00
5
2023-01-24
Chronic Spontaneous Urticaria
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-509859-13-00
5
2022-11-09
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-514394-22-00
6
2022-10-24
Actinic Keratosis
-
2024-516959-40-00
4
2021-08-17
This trial evaluates the efficacy and safety of Mirvetuximab soravtans
-
2023-508372-10-00
4
2021-05-19
Non small Cell Lung cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-507816-11-00
5
2020-08-17
Macular edema due to central retinal vein occlusion
-
2024-516271-32-00
5
2020-06-03
Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
-
2024-513914-36-00
4
2019-12-17
locally-advanced Anal Carcinoma, Anal cancer stage II and III
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2024-513464-26-00
5
2018-10-18
Multiple Myeloma
-
2024-514945-12-00
10
2018-09-03
locally advanced resectable adenocarcinoma of the oesophagogastric
jun
-
2023-505341-23-00
5
2018-07-27
Non-muscle invasive bladder cancer